文献速递MDS 与骨髓增殖性肿瘤造血干细胞移植与细胞治疗白血病

英国多中心真实世界研究:加速期与急变期骨髓增殖性肿瘤的治疗模式与结局

Real-world treatment patterns and outcomes in accelerated and blast-phase myeloproliferative neoplasms: Insights from a large multi-centre cohort analysis in the United Kingdom.
PubMed 文献 · Br J Haematol · 2026-05-03

这项英国回顾性多中心分析纳入2013至2025年诊断的175例费城染色体阴性骨髓增殖性肿瘤加速期(AP,n=69)或急变期(BP,n=106)患者,中位转化年龄71岁,中位随访45.2个月。中位总生存(OS)为14.9个月,BP期(6.7个月)显著差于AP期(25.3个月)。治疗选择在各中心间异质性强,强化化疗仅在后续桥接异基因造血干细胞移植(allo-HSCT)时改善结局(中位OS 24.7个月),芦可替尼为基础方案(尤其联合阿扎胞苷)在AP期显示可接受活性(中位OS 27.2个月),维奈克拉为基础方案全队列中位OS 14.9个月。

要点

  • MPN-AP/BP预后差,中位OS仅14.9个月,BP期(6.7个月)显著劣于AP期(25.3个月)。
  • 强化化疗仅在后续接受allo-HSCT时改善生存(中位OS 24.7个月)。
  • 芦可替尼联合阿扎胞苷在AP期显示可接受活性(中位OS 27.2个月)。

核心结论

  • 研究证实MPN-AP/BP预后差,英国缺乏统一共识方案,亟需改进疗法及前瞻性研究确定最佳治疗。

研究设计与样本

  • 英国多中心回顾性分析,纳入2013至2025年诊断的175例费城染色体阴性MPN-AP(n=69)或MPN-BP(n=106)患者。
  • 中位转化年龄71岁,中位随访45.2个月。

主要发现

  • 全队列中位OS为14.9个月,MPN-BP中位OS 6.7个月,显著差于MPN-AP的25.3个月。
  • 强化化疗仅在后续接受allo-HSCT时改善结局,中位OS 24.7个月。
  • 芦可替尼为基础方案(尤其联合阿扎胞苷)在AP期显示可接受活性,中位OS 27.2个月。
  • 维奈克拉为基础方案全队列中位OS为14.9个月。
  • 多变量分析显示强化化疗和维奈克拉为基础治疗与更好结局独立相关(反映患者选择),TP53突变预测生存更差。

关键数值与推荐

  • 强化化疗伴发热性中性粒细胞减少和脓毒症发生率高;维奈克拉与持续性血细胞减少相关。

临床怎么用

  • 强化化疗宜作为allo-HSCT的桥接策略,单纯强化化疗未显示生存获益。
  • AP期可考虑芦可替尼联合阿扎胞苷方案;BP期预后极差,需积极评估移植可行性。
  • TP53突变提示生存更差,应纳入风险分层与治疗决策参考。

局限性

  • 回顾性设计,治疗选择存在患者选择偏倚,多变量分析结果需谨慎解读。
  • 各中心治疗选择异质性强,缺乏统一方案,可能影响结局比较。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This UK-based retrospective analysis describes real-world treatment patterns and outcomes in 175 patients with accelerated (AP, n = 69) or blast-phase (BP, n = 106) 'Philadelphia-negative' myeloproliferative neoplasms (MPN-AP/BP) diagnosed between 2013 and 2025. Median age at transformation was 71 years. With a median follow-up of 45.2 months, median overall survival (OS) was 14.9 months, significantly worse for MPN-BP (6.7 months) versus MPN-AP (25.3 months). Treatment selection was heterogeneous across centres. Intensive chemotherapy (IC) improved outcomes only when followed by allogeneic haematopoietic stem cell transplant (allo-HSCT) (median OS 24.7 months). Ruxolitinib-based regimens, particularly combined with azacitidine, showed acceptable activity in AP (median OS 27.2 months). Venetoclax-based regimens achieved a median OS of 14.9 months across the cohort. Multivariable analysis identified IC and venetoclax-based therapy as independently associated with better outcomes, reflecting patient selection, while TP53 mutations predicted inferior survival. IC carried high rates of febrile neutropenia and sepsis; venetoclax was associated with prolonged cytopenias. This study confirms the poor prognosis of MPN-AP/BP, the absence of a unified UK consensus approach and the need for improved therapies and prospective studies to determine optimal treatment approaches for this challenging cohort.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Rampotas A, Naylor-Layland G, Brown C, et al. Real-world treatment patterns and outcomes in accelerated and blast-phase myeloproliferative neoplasms: Insights from a large multi-centre cohort analysis in the United Kingdom. Br J Haematol. 2026. PMID: 42070782. doi:10.1111/bjh.70511

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。